AzTrials
AzTrials

Stress Urinary IncontinenceNCT03958695

A Tunable-tension Transobturator Tape vs Standard Transobturator Midurethral Tape for Stress Urinary Incontinence

A study testing Tunable-tension transobturator tape, Urosling-T (Lintex, LLC) and Transobturator mid-urethral tape, Urosling (Lintex, LLC) in people with Stress Urinary Incontinence, run by Saint Petersburg State University, Russia at 2 sites in Russia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is the prospective randomized parallel groups trial with two participating centers (Department of Urology, Saint Petersburg State University Clinic of advanced medical technologies n.a. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Stress Urinary Incontinence
What is being tested?
Tunable-tension transobturator tape, Urosling-T (Lintex, LLC) and Transobturator mid-urethral tape, Urosling (Lintex, LLC)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
320 participants
Where
2 sitesRussia
Study dates
1 Apr 2020to 1 Apr 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The subject is a woman with stress urinary incontinence or urodynamic mixed urinary incontinence with predominate SUI
  • The subject is at least 18 years of age
  • The subject has failed conservative treatment for at least 6 months
  • The subject gave written consent to participate in the study,

Who cannot join

  • The subject has an active urinary tract infection or skin infection in the region of surgery
  • The subject has pelvic organ prolapse (POP) stage 2 or higher according to Pelvic Organ Prolapse Quantification system (POP-Q)
  • The subject had prior surgery for SUI or POP
  • The subject has predominate urge urinary incontinence
  • The subject has a urogenital fistula, anatomical defect, stricture, diverticulum, new growth or any kind of abnormalities of the urethra
  • The subject has chronic pelvic pain
Show all 13Show fewer
  • The subject has a system neurological disease, such as Parkinson's disease, Alzheimer disease and other dementias, multiple sclerosis, epilepsy etc
  • The subject has pelvic cancer or the subject has undergone radiotherapy for treating pelvic cancer
  • The subject has post void residual (PVR) >50 ml
  • The subject has dysfunctional voiding and average flow rate (Qave) < 12 ml/s
  • The subject is pregnant or disagrees to abstain from the pregnancy during the study
  • The subject has any mental disorders affecting his ability to evaluate the risks of the treatment and make an independent decision on participation in the study
  • The subject has an allergy on local anesthetics

Trial locations and contacts

2 sites in 1 country.

Russia2 sites
  • Regional Clinic Hospital №3

    Chelyabinsk, 454021

  • Saint Petersburg State University Clinic of advanced medical technologies n.a. N.I.Pirogov

    Saint Petersburg, 190103

Other trials in Russia

About this study

Official title: A Randomized Clinical Trial Comparing a Tunable-tension Transobturator Tape (TTT) Versus Standard Transobturator Midurethral Tape (TOT) for the Surgical Treatment of Stress Urinary Incontinence in Women

This is the prospective randomized parallel groups trial with two participating centers (Department of Urology, Saint Petersburg State University Clinic of advanced medical technologies n.a. N.I.Pirogov, Saint Petersburg, Russia; Department of Urology, Regional Hospital №3, Chelyabinsk, Russia) designed to assess the efficacy and safety of tunable-tension transobturator tape and its ability to reduce the rate of postoperative voiding dysfunction comparing to standard transobturator midurethral sling.

Read the detailed description

BACKGROUND A minimally invasive midurethral sling procedure is a favorite primary surgical method for the treatment of stress urinary incontinence (SUI). It is considered one of the most effective and safe anti-incontinence surgeries. The observed objective cure rate for transobturator sling is about 90%. However, this number may be wily because in most studies it does not exclude patients who achieved continence, but had voiding dysfunction. It is one of the most common complications of the midurethral sling, associated with the excess tape tension. The estimated rate of postoperative voiding dysfunction is up to 25%. There are few methods that allow to decrease tape tension after the surgery, such as urethral dilatation, sling mobilization, sling incision, complete excision of the tape and urethrolysis. All these methods are invasive, poorly controlled by the surgeon and are associated with the risk of recurrence of stress urinary incontinence.

PREOPERATIVE ASSESSMENT All patients who meet eligibility criteria will undergo a preoperative assessment: a detailed medical history, physical examination, vaginal examination, ICS-Uniform Cough Stress Test (ICS-UCST), uroflowmetry and ultrasound measurement of post-void residual volume (PVR). All patients will complete specific questionnaires, validated in Russia: Urogenital Distress Inventory 6 (UDI-6), International Conférence on Incontinence Questionnaire-Short Form (ICIQ-SF), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PICQ-12). The patients who will answer "Yes" to the question: "Do you experience urine leakage related to the feeling of urgency?" in UDI-6 questionnaire will undergo a urodynamic study to assess the presence and severity of detrusor overactivity.

MATERIALS AND METHODS The hypothesis is that TTT is non-inferior to TOT for SUI treatment. The sample size was calculated assuming an objective cure rate of 85% with TOT using a limit of equivalence of d=0,1 with 80% power. Thus 149 patients in each group are needed. We assume a drop-out rate of 30%, so in total 388 participants will be included in the study.

All enrolled patients will be randomly assigned to TTT or TOT treatment groups in equal ratio the day before the surgery, using computer randomization. The randomization will be performed by one resident urologist, who has no access to patients' data.

All surgical interventions will be performed by 4 urologists, performing at least 100 TOT surgeries per year. The next day after the surgery uroflowmetry values and PVR will be determined in all patients. In case of bladder outlet obstruction (BOO) symptoms, patients from TOT group will be recommended an intermittent self-catheterization for 6 weeks, or a urethral dilatation for choice. Patients from TTT group with BOO will undergo a procedure of non-invasive loosening of the tape under local anesthesia. The algorithm of uroflowmetry, PVR and tuning of the tape will be repeated until normal outflow values will be achieved. Also in patients from the TTT group, ICS-UCST will be estimated. If a patient will be experienced leakage a non-invasive tensioning of the tape under local anesthesia will be performed followed by uroflowmetry, PVR and additional tuning if necessary, until optimal tension will be achieved. The examination will be repeated on the day of discharge.

The postoperative assessment will be performed by 2 urologists, who will be blinded about the type of intervention.

Being tested
Tunable-tension transobturator tape, Urosling-T (Lintex, LLC), Transobturator mid-urethral tape, Urosling (Lintex, LLC)
Keywords
midurethral sling, stress urinary incontinence, urinary incontinence, voiding dysfunction
Medical subject headings
Urinary Incontinence, Stress, Urinary Incontinence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)Device

    A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period

  • Transobturator mid-urethral tape, Urosling (Lintex, LLC)Device

    A transobturator tension-free mid-urethral sling

Study groups in NCT03958695
Study groupRoleWhat they receive
Tunable-tension transobturator tape (TTT)Active comparatorNot described
Receives: Device: Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)
Transobturator mid-urethral tape (TOT)Active comparatorNot described
Receives: Device: Transobturator mid-urethral tape, Urosling (Lintex, LLC)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective cure of stress urinary incontinence

    Objective cure is defined as the absence of urinary leakage during ICS-Uniform Cough Stress Test (ICS-UCST) in the absence of the bladder outlet obstruction

    Measured: 36 months (3 years)

Secondary outcomes (7)
  1. Observed postoperative bladder outlet obstruction

    Defined as average urine flow rate <12 ml/s or/and post void residual > 50 ml or/and urine retention

    Measured: Measured postoperatively at intervals of 1, 6, 12, 24 and 36 months postoperatively (3 years in total)

  2. Subjective cure of stress urinary incontinence

    Defined as an aswer "Never" to the question "Do you experience urine leakage related to physical activity, coughing or sneezing?" in UDI-6 questionnaire

    Measured: Measured postoperatively at intervals of 1, 6, 12, 24 and 36 months postoperatively (3 years in total)

  3. Observed postoperative voiding dysfunction

    Defined as the presence of any of the following complaints: slow urine stream, need to strain for voiding, intermittent stream, spraying, inability to void, incomplete bladder emptying, position-dependent voiding

    Measured: Measured postoperatively at intervals of 1, 6, 12, 24 and 36 months postoperatively (3 years in total)

  4. Observed complications

    Presense of any adverse effects such as: bleeding, haematoma, organ perforation, wound infection, urinary tract infection, pelvic pain, mesh extrusion in the vagina, mesh erosion into the urinary tract, dyspareunia de novo, de novo urgency

    Measured: Measured postoperatively at intervals of 1, 6, 12, 24 and 36 months postoperatively (3 years in total)

  5. The assessment of the impact of treatment on the quality of life: Urogenital Distress Inventory (UDI-6) questionnaire

    Measured through the Urogenital Distress Inventory (UDI-6) questionnaire, validated in Russia. The score varies from 0 to 100. The basic interpretation of the score is that the higher the score, the worse the outcome.

    Measured: Measured postoperatively at intervals of 12, 24 and 36 months postoperatively (3 years in total)

  6. The assessment of self-reported success of the treatment

    Measured through the International Conférence on Incontinence Questionnaire Short Form (ICIQ-SF) questionnaire, validated in Russia. The questionnaire is a subjective measure of severity of urinary loss and patients' quality of life. The score varies from 0 to 21. The higher the score indicates greater severity of urinary incontinence: 1-5 - slight, 6-12 - moderate, 13-18 - severe, 19-21 - very severe.

    Measured: Measured postoperatively at intervals of 12, 24 and 36 months postoperatively (3 years in total)

  7. The assessment of the impact of treatment on sexual function

    Measured through the scoring of Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) validated in Russia. The scale evaluates sexual function in patients with urinary incontinence and/or POP. The responses are graded on a five-point Likert scale ranging from 0 (always) to 4 (never). Items 1 - 4 are reversely scored and a total of 48 is the maximum score. The higher scores indicate better sexual function. Up to two missing responses are accepted. The total score sum with missing values is calculated by multiplying the number of items by the mean of the responses to the items reported by that person.

    Measured: Measured postoperatively at intervals of 12, 24 and 36 months postoperatively (3 years in total)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 May 2019
  2. Study start1 Apr 2020
  3. Primary completion1 Jan 2023
  4. Study completion1 Apr 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
320 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03958695
Sponsor's protocol ID
TTTvsTOT
Status last verified
May 2023
First submitted
5 May 2019
Last updated
3 May 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Tunable-tension transobturator tape, Urosling-T (Lintex, LLC) and Transobturator mid-urethral tape, Urosling (Lintex, LLC) in people with Stress Urinary Incontinence, run by Saint Petersburg State University, Russia at 2 sites in Russia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 May 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective cure of stress urinary incontinence (time frame: 36 months (3 years)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in